Development of a pharmacokinetic/pharmacodynamic evaluation model for osteomyelitis and usefulness of tedizolid as an alternative to vancomycin against MRSA osteomyelitis
Journal of Pharmacy and Pharmacology · 2025
DOI: 10.1093/jpp/rgae124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2025. Verfasst von Xiaoxi Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, 1-5-30 Shiba koen, Minato-ku, Tokyo 105-8512, Japan. Hauptthemen laut MEDLINE: Osteomyelitis, Vancomycin, Methicillin-Resistant Staphylococcus aureus, Anti-Bacterial Agents. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
This study aimed to develop a suitable osteomyelitis model for pharmacokinetic/pharmacodynamic (PK/PD) evaluation and to investigate the target PK/PD values of vancomycin and tedizolid against methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis.
Methods
An osteomyelitis model was established by implanting an MRSA-exposed sterilized suture in the tibia of normal mice and mice with cyclophosphamide-induced neutropenia. The suitability of the osteomyelitis mouse model for PK/PD evaluation was assessed using vancomycin as an indicator. The target PK/PD values for tedizolid were determined using this model. Key findings In neutropenic mice, to achieve a static effect and 1 log10 kill against MRSA, the ratios of the area under the free drug concentration–time curve for 24 h to the minimum inhibitory concentration (fAUC24/MIC) of vancomycin were 91.29 and 430.03, respectively, confirming the validity of the osteomyelitis model for PK/PD evaluation. In immunocompetent mice, the target fAUC24/MIC values of tedizolid for achieving a static effect and 1 log10 kill against MRSA were 2.40 and 49.20, respectively. Additionally, only a 0.28 log10 kill was achieved in neutropenic mice with 20 times the human equivalent dose of tedizolid.
Conclusions
In patients with restored immunity, tedizolid can potentially be used as an alternative to intravenous vancomycin therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, 1-5-30 Shiba koen, Minato-ku, Tokyo 105-8512, Japan.
ORCID-Profile: Yuki Enoki
Zitieren
APA
Liu, X., Enoki, Y., Taguchi, K., & Matsumoto, K. (2025). Development of a pharmacokinetic/pharmacodynamic evaluation model for osteomyelitis and usefulness of tedizolid as an alternative to vancomycin against MRSA osteomyelitis. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgae124
Vancouver
Liu X, Enoki Y, Taguchi K, Matsumoto K. Development of a pharmacokinetic/pharmacodynamic evaluation model for osteomyelitis and usefulness of tedizolid as an alternative to vancomycin against MRSA osteomyelitis. Journal of Pharmacy and Pharmacology. 2025. doi:10.1093/jpp/rgae124
BibTeX
@article{Liu2025,
author = {Liu, Xiaoxi and Enoki, Yuki and Taguchi, Kazuaki and Matsumoto, Kazuaki},
title = {Development of a pharmacokinetic/pharmacodynamic evaluation model for osteomyelitis and usefulness of tedizolid as an alternative to vancomycin against MRSA osteomyelitis},
journal = {Journal of Pharmacy and Pharmacology},
year = {2025},
doi = {10.1093/jpp/rgae124}
}
EUVIMED